Glossary
Zepbound
Updated March 29, 2026
Zepbound is a weekly tirzepatide injection approved for chronic weight management. It contains the same active ingredient as Mounjaro but carries a weight-loss indication and is prescribed specifically for fat-loss outcomes. Tirzepatide's dual GIP/GLP-1 mechanism produces very strong appetite suppression, making calorie deficit adherence easy but under-eating a serious risk for anyone trying to preserve muscle during a cut.
Quick reference
| Item | Detail |
|---|
| Active ingredient | tirzepatide |
| Medication family | dual GIP/GLP-1 receptor agonist |
| Form | weekly subcutaneous injection |
| Titration schedule | 2.5mg (weeks 1-4), 5mg (weeks 5-8), 7.5mg (weeks 9-12), 10mg (weeks 13-16), option for 12.5mg and 15mg |
| When appetite effects start | most people notice meaningful hunger reduction at 5mg, with strongest effects at 10mg and above |
| Clinical indication | chronic weight management (FDA-approved for BMI 30+ or 27+ with comorbidity) |
What Zepbound's titration means for training people
Each dose step intensifies appetite suppression. The jump from 5mg to 7.5mg and from 10mg to 12.5mg are the most common points where people start under-eating without realizing it.
| Dose phase | Typical appetite effect | Nutrition priority |
|---|
| 2.5-5mg (weeks 1-8) | moderate hunger reduction | build protein tracking habits and meal templates before suppression intensifies |
| 7.5-10mg (weeks 9-16) | strong suppression, food noise mostly gone | enforce 1.4-1.6 g/kg protein daily, switch to structured meals (3-4 per day, protein-first) |
| 12.5-15mg (week 17+) | very strong suppression, some meals feel difficult | simplify protein formats (shakes, Greek yogurt, deli turkey), use default meal templates, consider 4-5 smaller meals |
Physique-first cut protocol
| Control point | Specific targets | Practical examples | What it prevents |
|---|
| Deficit sizing | 15-25% below maintenance (300-500 cal/day) | if maintenance is 2,200 cal, target 1,700-1,900 cal | strength loss and rebound hunger |
| Protein floor | 1.4-1.6 g/kg daily, 30-40g per meal (higher floor than single GLP-1 drugs) | 5 oz chicken (~44g), 6 oz salmon (~34g), 1 cup cottage cheese (~28g), protein shake + yogurt (~45g) | lean mass loss during rapid weight change |
| Fiber + hydration | 25-30g fiber daily (ramp by 3-5g/week), 64-80 oz water daily | 1/2 cup lentils (~8g), 1 oz chia seeds (~10g), 1 cup broccoli (~5g), 32 oz bottle x2 | constipation and GI disruption |
| Training consistency | 3-4 resistance sessions per week, reduce volume before dropping frequency | squat, bench, row, deadlift or variations | "scale down, physique down" outcomes |
Side-effect management specific to Zepbound
| Issue | When it typically peaks | Foods and actions that help |
|---|
| Nausea | first 3-5 days after each dose increase, worst at the 7.5mg and 10mg steps | eat slowly (15-20 min), keep meals under 400 cal until stable, choose bland foods (rice, toast, broth, cold yogurt), avoid greasy foods |
| Constipation | common at 10mg+ as food volume drops further | ramp fiber by 3-5g per week, add 16-24 oz water daily, ground flaxseed and chia seeds in shakes |
| Bloating and fullness | tirzepatide slows gastric emptying more than single GLP-1 drugs | eat smaller meals (300-400 cal) more frequently (4-5 per day), avoid carbonated drinks |
Monitoring and adjustment
| Signal | What it means | Next move |
|---|
| Weight down but performance down | deficit and recovery cost are too high | increase intake by 200-300 cal, prioritize protein and pre-workout carbs |
| Hunger rebounds late at night | earlier meals lacked protein, fiber, or planned fats | shift 30-40% of daily protein and fiber to breakfast and lunch |
| Plateau over 2+ weeks with good adherence | normal adaptation or hidden drift | follow weight loss plateau checks, use 14-day trend window before changing targets |
| Losing more than 1.5 lb per week consistently | deficit likely too aggressive for muscle preservation | raise intake and recheck trend in 2 weeks |
Safety and escalation thresholds
| Signal pattern | Why it matters | Next step |
|---|
| Severe abdominal pain with persistent vomiting | pancreatitis or gallbladder complication risk | urgent clinical evaluation |
| Persistent dehydration signs or inability to keep fluids down | kidney and electrolyte stress risk | seek medical guidance |
| Severe weakness or confusion | systemic risk | urgent evaluation |